Ioannidis strikes again

“The need to consider the wider agenda in systematic reviews and meta-analysis: breadth, timing, and depth of the evidence.”

Ioannidis and colleague are at it once again, looking at the quality of evidence that gives rise to the approval and eventual widespread use of clinical pharmaceuticals. In this case, they show that a common cancer drug is substantially less effective that is assumed by existing meta-analysis, the evidence used to approve the drug, and probably the doctors using the drug on a day-to-day basis. Drug companies dominate evidence and this can only be a bad thing for safety and efficacy.

Click the title to see the article.

Ioannidis strikes again

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s